Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 7-valent conjugate vaccine (Pfizer)
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 7-valent pneumococcal conjugate vaccine (PCV7) is a sterile solution of saccharides of the capsular antigens of *Streptococcus pneumoniae* serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, individually conjugated to the diphtheria CRM197 protein. Developed by Wyeth (now Pfizer), it was the first conjugate vaccine approved for the prevention of invasive pneumococcal disease in infants and young children. By conjugating the polysaccharide antigens to a protein carrier, the vaccine induces a T-cell dependent immune response, which is effective in children under two years of age, unlike plain polysaccharide vaccines. While highly effective in reducing the burden of vaccine-type pneumococcal disease, it has been largely superseded in many national immunization programs by higher-valency versions like PCV13 and PCV20.
- Brand names
- PrevenarPrevnar
- Other names
- 7-valent pneumococcal conjugated vaccine7-valent pneumococcal conjugate vaccine7vPCV
02
Targets
CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)
Beyond the preview
Go deeper on pneumococcal 7-valent conjugate vaccine (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 7-valent conjugate vaccine (Pfizer).